MRK vs ORCL: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Oracle Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
VS
Oracle Corporation · Technology
$184.31
+14.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
ORCL has more upside to fair value
(+14.0%).
ORCL trades at a lower forward P/E
(31.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
ORCL |
| Current Price |
$113.87 |
$184.31 |
| Fair Value Estimate |
$100.14 |
$210.13 |
| Upside to Fair Value |
-12.1%
|
+14.0%
|
| Market Cap |
$281.2B |
$530.1B |
| Forward P/E |
32.0x
|
31.0x
|
| EV / EBITDA |
17.3x
|
20.4x
|
| Price / Sales |
4.3x
|
7.9x
|
| Price / FCF |
19.9x
|
-22.4x
|
| Revenue Growth YoY |
+4.3%
|
+20.6%
|
| Gross Margin |
75.9%
|
65.8%
|
| Operating Margin |
27.6%
|
30.8%
|
| Return on Equity |
17.9%
|
50.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.02%
|
—
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Oracle Corporation is a leading enterprise software and cloud infrastructure provider with a durable competitive moat driven by its extensive software portfolio, strong cloud growth, and stable leadership. The company reported $57.4 billion in revenue for fiscal 2025, growing 8% year-over-year, with cloud services and license support growing 12%. Oracle's cloud infrastructure (OCI) is a key growt…
Accumulation Zones
| Metric |
MRK |
ORCL |
| Zone Low |
$75.11 |
$157.60 |
| Zone High |
$85.12 |
$178.61 |
| In Buy Zone? |
No
|
No
|